Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
91 hedge funds and large institutions have $291M invested in Eiger BioPharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 24 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
83% more call options, than puts
Call options by funds: $4.16M | Put options by funds: $2.28M
60% more capital invested
Capital invested by funds: $182M → $291M (+$109M)
11% less funds holding
Funds holding: 102 → 91 (-11)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$24.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$2.41M |
| 4 |
Millennium Management
New York
|
+$1.47M |
| 5 |
BlackRock
New York
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.89M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.77M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.74M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.04M |
| 5 |
CCM
Copernicus Capital Management
San Francisco,
California
|
-$1.94M |
EIGR Hedge Fund Activity: Q4 2020 in Review
91 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2020, worth a combined $291M — up 60% from $182M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of EIGR and 13 opened new positions — a net loss of 11 holders — while 19 trimmed existing stakes and 42 added.
The largest buyer was Ameriprise, adding an estimated $24.2M. The largest seller was Mangrove Partners, exiting entirely with an estimated $8.89M sold.
- 91 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2020, down from 102 in Q3 2020.
- Funds reported $291M of Eiger BioPharmaceuticals, Inc. stock for Q4 2020, up 60% quarter-over-quarter.
- 13 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2020 and 24 closed out, a net change of -11 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2020 was Ameriprise, an estimated $24.2M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2020 was Mangrove Partners, an estimated $8.89M sold.
Based on aggregated 13F filings for Q4 2020.